Jakafi, also known by its generic name ruxolitinib, is manufactured by Incyte Corporation [1]. The company's manufacturing facilities are primarily located in the United States [2]. Specifically, Incyte operates a drug product manufacturing facility in Delaware [2].
Who else makes ruxolitinib?
While Incyte Corporation is the originator and primary manufacturer of Jakafi (ruxolitinib), other companies may produce generic versions of the drug once patents and exclusivity periods expire [3]. These companies typically require regulatory approval from bodies like the U.S. Food and Drug Administration (FDA) before they can market their versions [4]. Information on specific generic manufacturers and their production locations is often detailed in regulatory filings and patent databases [3, 5].
When does Jakafi's patent expire?
The patent landscape for Jakafi (ruxolitinib) is complex, involving multiple patents covering the drug substance, methods of use, and formulations [5]. Patent expiry dates can vary depending on the specific patent and jurisdiction. DrugPatentWatch.com tracks these patent expiries, providing detailed information on when market exclusivity for branded drugs like Jakafi is expected to end, paving the way for potential generic competition [5].
What conditions does Jakafi treat?
Jakafi is approved to treat several conditions. It is used for the treatment of intermediate or high-risk myelofibrosis (MF), including primary MF, post-polycythemia vera MF, and post-essential thrombocythemia MF, in adults [1]. It is also indicated for the treatment of polycythemia vera (PV) in adults who have had an inadequate response to or are intolerant of hydroxyurea [1]. Additionally, Jakafi is used to treat steroid-refractory acute graft-versus-host disease (GVHD) in pediatric patients one year and older, and in adults [1].
How does ruxolitinib work?
Ruxolitinib is a Janus kinase (JAK) inhibitor [1]. It works by inhibiting JAK1 and JAK2 enzymes, which play a role in signaling pathways involved in blood cell formation and immune function [1]. By blocking these pathways, ruxolitinib helps to reduce the overproduction of blood cells and the inflammatory processes associated with certain myeloproliferative neoplasms and GVHD [1].
What are the risks and side effects of Jakafi?
Jakafi can cause serious side effects, including serious and fatal infections, and the development of certain cancers [1]. Common side effects include low blood cell counts (anemia, thrombocytopenia, neutropenia), diarrhea, nausea, abdominal pain, and fatigue [1]. Patients are advised to discuss potential risks and side effects with their healthcare provider [1].
Sources:
[1] https://www.jakafi.com/
[2] https://www.businesswire.com/news/home/20130805005134/en/Incyte-Corporation-Announces-Completion-of-Drug-Product-Manufacturing-Facility-in-Delaware
[3] https://www.fda.gov/
[4] https://www.accessdata.fda.gov/scripts/cder/daf/
[5] https://drugpatentwatch.com/